Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.38 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.38 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.38 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.38 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.38 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17481683 | 1.00 | ALDH1A1 (0.40) | ALDH1A1LMNAKDM4EHTTSMN1; SMN2 | |
| SCHEMBL16056705 | 1.00 | ALDH1A1 (0.40) | ALDH1A1LMNAKDM4EHTTSMN1; SMN2 | |
| SCHEMBL17476069 | 1.00 | ALDH1A1 (0.40) | ALDH1A1LMNAKDM4EHTTSMN1; SMN2 | |
| SCHEMBL16056704 | 1.00 | ALDH1A1 (0.40) | ALDH1A1LMNAKDM4EHTTSMN1; SMN2 | |
| Bromide SCHEMBL17476062 | 0.98 | ALDH1A1 (0.39) | ALDH1A1LMNAKDM4EHTTSMN1; SMN2 | |
| Bromide SCHEMBL17476064 | 0.98 | ALDH1A1 (0.39) | ALDH1A1LMNAKDM4EHTTSMN1; SMN2 | |
| SCHEMBL25798285 | 0.98 | ALDH1A1 (0.42) | ALDH1A1LMNAKDM4EHTTSMN1; SMN2 | |
| Bromide SCHEMBL17476061 | 0.98 | ALDH1A1 (0.39) | ALDH1A1LMNAKDM4EHTTSMN1; SMN2 | |
| SCHEMBL12598284 | 0.95 | PSEN1 (0.42) | ALDH1A1LMNAKDM4EHTTSMN1; SMN2 | |
| SCHEMBL8199946 | 0.95 | PSEN1 (0.42) | ALDH1A1LMNAKDM4EHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2682409-B1 | DERIVATIVE OF HYALURONIC ACID MODIFIED WITH AMINO-CARBOXYLIC ACID | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2017-07-05 | — | — | EP | disclosed |
| EP-3184553-A1 | DERIVATIVE OF HYALURONIC ACID MODIFIED WITH AMINO-CARBOXYLIC ACID | Chugai Seiyaku Kabushiki Kaisha (JP) | 2017-06-28 | — | — | EP | disclosed |
| US-9243077-B2 | Derivative of hyaluronic acid modified with amino-carboxylic acid | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-01-26 | — | — | US | disclosed |
| US-9243077-B2 | Derivative of hyaluronic acid modified with amino-carboxylic acid | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-01-26 | — | — | US | disclosed |
| WO-2012118189-A1 | HYALURONIC ACID DERIVATIVE MODIFIED BY AMINO-CARBONIC ACID | 中外製薬株式会社 (JP) | 2012-09-07 | — | — | WO | disclosed |
| US-20120071329-A1 | METHODS FOR IDENTIFYING COMPOUNDS OF INTEREST USING ENCODED LIBRARIES | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | US | disclosed |
| US-20110251089-A1 | METHODS FOR SYNTHESIS OF ENCODED LIBRARIES | GLAXOSMITHKLINE (US) | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251089-A1 | METHODS FOR SYNTHESIS OF ENCODED LIBRARIES | RNGTT, DTYMK, DUT | ALDH1A1 2470/4885LMNA 3319/4885KDM4E 4000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.